Results from the REWIND trial, investigating dulaglutide for cardiovascular outcomes in type 2 diabetes, were published on 2019-01-01. This pivotal study, a double-blind, randomized, placebo-controlled trial, examined the drug's effects in patients with type 2 diabetes.
Background
Dulaglutide (Trulicity) is a medication studied for its effects in type 2 diabetes. The REWIND trial specifically focused on its impact on cardiovascular outcomes in this patient population, representing a key area of research given the high comorbidity of cardiovascular disease with type 2 diabetes.
Trial design
The REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) trial was a double-blind, randomized, placebo-controlled trial. It investigated dulaglutide in patients with type 2 diabetes, comparing its effects against placebo to assess its influence on cardiovascular outcomes.
What this means
The publication of the REWIND trial results provides important data regarding dulaglutide's effects on cardiovascular outcomes in individuals with type 2 diabetes. As a major pivotal publication, these findings contribute significantly to the understanding of dulaglutide's profile beyond glycemic control, offering insights for clinicians managing patients with type 2 diabetes at cardiovascular risk.
Source
The information regarding the REWIND trial publication was sourced from PubMed. The article, titled 'Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial', was published on 2019-01-01 and is available via pubmed.ncbi.nlm.nih.gov.